注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
Deciphera Pharmaceuticals Inc是一家專注於發現、開發和提供藥物治療癌症患者的生物製藥公司。該公司開發了激酶生物學的開關控制激酶抑制劑平臺,以執行其戰畧,開發廣泛的藥物組合。該公司已經準予了一種藥物,QINLOCK,這是一種開關控制激酶抑制劑,用於治療第四線胃腸道間質瘤(GIST)。此外,該公司正在開發三種臨床階段候選藥物,其中包括Vimseltinib(DCC-3014)-集落刺激因數1受體(CSF1R)激酶抑制腱鞘巨細胞瘤(TGCT),Rebastinib-TEK酪氨酸激酶(TIE2)激酶抑制晚期或轉移性實體瘤,和DCC-3116-ULK激酶抑制突變RAS/RAF癌。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Steven L. Hoerter | 50 | 2018 | President, CEO & Director |
James A. Bristol | 76 | 2007 | Independent Director |
John S. Condeelis | - | - | Member of Scientific Advisory Board |
Dennis Leo Walsh | 55 | 2015 | Independent Director |
Jean-Yves Blay | 61 | 2015 | Member of Scientific Advisory Board |
Ron Squarer | 56 | 2019 | Independent Chairman |
Filip Janku | 48 | 2015 | Member of Scientific Advisory Board |
Michele De Palma | - | - | Member of Scientific Advisory Board |
John de Groot | - | - | Member of Scientific Advisory Board |
Patricia L. Allen | 61 | 2016 | Independent Director |
Frank S. Friedman | 65 | 2019 | Independent Director |
F. Stephen Hodi | - | 2015 | Member of Scientific Advisory Board |
John R. Martin | 62 | 2015 | Independent Director |
Edward J. Benz | 77 | 2016 | Independent Director |
Susan L. Kelley | 68 | 2019 | Independent Director |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核